Literature DB >> 20062959

[Differentiated therapy of liver tumors].

B Boozari1, S Kubicka.   

Abstract

Focal nodular hyperplasia is a polyclonal hyperplasia of liver cells as a result of locally enhanced blood flow because of vessel malformations. Only symptomatic FNH is an indication for resection or enucleation. In contrast to FNH growth of adenoma is dependent on sexual hormones. Solitary HNFalpha-inactivated and inflammatory adenomas larger than 5 cm should be removed because of risk of tumor rupture or bleeding, while beta-catenin mutated adenomas should be surgically removed at any stage because of risk of malignant transformation. The prognosis of patients with HCC is dependent on the tumor stage, but also on the liver function. Resection is the treatment of choice for HCC in patients without liver cirrhosis. Patients with liver cirrhosis and early HCC without extrahepatic metastasis can be successfully treated by liver transplantation. If transplantation is not possible these tumors should be removed by local percutaneous ablation. Transarterial chemoembolization is an effective treatment for more advanced HCC in patients with good liver function. Studies showed that the multikinase inhibitor sorafenib significantly improves survival of patients with advanced or metastatic HCC in child A cirrhosis. The only curative option for patients with intrahepatic cholangiocarcinomas is surgical resection. Patients with unresectable cholangiocarcinomas should be treated with a chemotherapy consisting of Gemcitabine-Cisplatin-combination.

Entities:  

Mesh:

Year:  2010        PMID: 20062959     DOI: 10.1007/s00108-009-2526-4

Source DB:  PubMed          Journal:  Internist (Berl)        ISSN: 0020-9554            Impact factor:   0.743


  20 in total

1.  Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL conference. European Association for the Study of the Liver.

Authors:  J Bruix; M Sherman; J M Llovet; M Beaugrand; R Lencioni; A K Burroughs; E Christensen; L Pagliaro; M Colombo; J Rodés
Journal:  J Hepatol       Date:  2001-09       Impact factor: 25.083

2.  Oral contraceptive use and focal nodular hyperplasia of the liver.

Authors:  D Mathieu; H Kobeiter; P Maison; A Rahmouni; D Cherqui; E S Zafrani; D Dhumeaux
Journal:  Gastroenterology       Date:  2000-03       Impact factor: 22.682

3.  [Systemic treatment of liver and biliary tumors].

Authors:  N P Malek; T Greten; S Kubicka
Journal:  Internist (Berl)       Date:  2007-01       Impact factor: 0.743

Review 4.  [Liver resection and transplantation for hepatic tumors].

Authors:  H Lang; C E Broelsch
Journal:  Internist (Berl)       Date:  2007-01       Impact factor: 0.743

5.  [Regional therapy of liver tumors].

Authors:  H C Spangenberg; L Mohr; H E Blum
Journal:  Internist (Berl)       Date:  2007-01       Impact factor: 0.743

Review 6.  Molecular pathogenesis and targeted therapy of hepatocellular carcinoma.

Authors:  Lars Zender; Stefan Kubicka
Journal:  Onkologie       Date:  2008-09-09

7.  Hepatocellular adenoma management and phenotypic classification: the Bordeaux experience.

Authors:  Paulette Bioulac-Sage; Hervé Laumonier; Gabrielle Couchy; Brigitte Le Bail; Antonio Sa Cunha; Anne Rullier; Christophe Laurent; Jean-Frédéric Blanc; Gaelle Cubel; Hervé Trillaud; Jessica Zucman-Rossi; Charles Balabaud; Jean Saric
Journal:  Hepatology       Date:  2009-08       Impact factor: 17.425

8.  Sorafenib in advanced hepatocellular carcinoma.

Authors:  Josep M Llovet; Sergio Ricci; Vincenzo Mazzaferro; Philip Hilgard; Edward Gane; Jean-Frédéric Blanc; Andre Cosme de Oliveira; Armando Santoro; Jean-Luc Raoul; Alejandro Forner; Myron Schwartz; Camillo Porta; Stefan Zeuzem; Luigi Bolondi; Tim F Greten; Peter R Galle; Jean-François Seitz; Ivan Borbath; Dieter Häussinger; Tom Giannaris; Minghua Shan; Marius Moscovici; Dimitris Voliotis; Jordi Bruix
Journal:  N Engl J Med       Date:  2008-07-24       Impact factor: 91.245

Review 9.  Systematic review of randomized trials for hepatocellular carcinoma treated with percutaneous ablation therapies.

Authors:  Yun Ku Cho; Jae Kyun Kim; Mi Young Kim; Hyunchul Rhim; Joon Koo Han
Journal:  Hepatology       Date:  2009-02       Impact factor: 17.425

Review 10.  Meta-analysis of percutaneous radiofrequency ablation versus ethanol injection in hepatocellular carcinoma.

Authors:  Carmen Bouza; Teresa López-Cuadrado; Raimundo Alcázar; Zuleika Saz-Parkinson; José María Amate
Journal:  BMC Gastroenterol       Date:  2009-05-11       Impact factor: 3.067

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.